Literature DB >> 6521718

Neuroimaging in multiple sclerosis.

J H Noseworthy, D W Paty, G C Ebers.   

Abstract

Conventional CT studies were the first neuroimaging tools shown to be frequently useful in the assessment of patients with multiple sclerosis. The most commonly noted abnormalities are cerebral atrophy, foci of decreased density, and contrast enhancing lesions. Hypodense lesions may represent either recent or remote sites of demyelination and this can be determined in part by the response of these abnormalities to contrast administration and by their evolution with serial CT studies. There is compelling evidence that CT enhancing lesions correspond to sites of active inflammation and demyelination. High-volume delayed CT studies increase the number of CT abnormalities seen, particularly in patients examined at the time of clinical disease activity. These studies appear to be well-tolerated in properly hydrated patients with normal renal function. NMRI studies appear to be the most sensitive way to detect MS lesions and are particularly useful in demonstrating abnormalities in the posterior fossa. Less is known of the pathologic substrate and the evolution of these NMR abnormalities. It appears likely that NMR detected lesions usually do not resolve completely and consequently changes seen with this neuroimaging technique may represent the cumulative effects of past and present disease activity.

Entities:  

Mesh:

Year:  1984        PMID: 6521718

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  2 in total

1.  MRI parameters in multiple sclerosis patients.

Authors:  I Reider-Groswasser; E Kott; J Benmair; M Huberman; Y Machtey; I Gelernter
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

2.  Evaluation of the potassium channel tracer [18F]3F4AP in rhesus macaques.

Authors:  Nicolas J Guehl; Karla M Ramos-Torres; Clas Linnman; Sung-Hyun Moon; Maeva Dhaynaut; Moses Q Wilks; Paul K Han; Chao Ma; Ramesh Neelamegam; Yu-Peng Zhou; Brian Popko; John A Correia; Daniel S Reich; Georges El Fakhri; Peter Herscovitch; Marc D Normandin; Pedro Brugarolas
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-22       Impact factor: 6.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.